Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Long-Term Debt Issuances (2016 - 2020)

Historic Long-Term Debt Issuances for BioRestorative Therapies (BRTX) over the last 10 years, with Q4 2020 value amounting to $3.8 million.

  • BioRestorative Therapies' Long-Term Debt Issuances changed N/A to $3.8 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.3 million, marking a year-over-year change of. This contributed to the annual value of $4.3 million for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q4 2020, BioRestorative Therapies' Long-Term Debt Issuances is $3.8 million.
  • BioRestorative Therapies' 5-year Long-Term Debt Issuances high stood at $3.8 million for Q4 2020, and its period low was $200000.0 during Q1 2017.
  • In the last 5 years, BioRestorative Therapies' Long-Term Debt Issuances had a median value of $916526.0 in 2016 and averaged $1.3 million.
  • Per our database at Business Quant, BioRestorative Therapies' Long-Term Debt Issuances surged by 63101.5% in 2019 and then plummeted by 8562.87% in 2020.
  • Quarter analysis of 5 years shows BioRestorative Therapies' Long-Term Debt Issuances stood at $780000.0 in 2016, then surged by 48.36% to $1.2 million in 2017, then skyrocketed by 72.42% to $2.0 million in 2018, then soared by 54.06% to $3.1 million in 2019, then rose by 25.2% to $3.8 million in 2020.
  • Its last three reported values are $3.8 million in Q4 2020, $441762.0 for Q1 2020, and $3.1 million during Q1 2019.